Citation: | Yuan Shun, Wang Zhiwei. Research progress on myeloid-derived suppressor cell and transplantation immune tolerance[J]. ORGAN TRANSPLANTATION, 2020, 11(4): 435-442. doi: 10.3969/j.issn.1674-7445.2020.04.002 |
[1] |
FLEMING V, HU X, WEBER R, et al. Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression[J]. Front Immunol, 2018, 9: 398. DOI: 10.3389/fimmu.2018.00398.
|
[2] |
ZHANG W, LI J, QI G, et al. Myeloid-derived suppressor cells in transplantation: the dawn of cell therapy[J]. J Transl Med, 2018, 16(1): 19. DOI: 10.1186/s12967-018-1395-9.
|
[3] |
GARCIA AJ, RUSCETTI M, ARENZANA TL, et al. Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression[J]. Mol Cell Biol, 2014, 34(11): 2017-2028. DOI: 10.1128/MCB.00090-14.
|
[4] |
FUJⅡ W, ASHIHARA E, HIRAI H, et al. Myeloid-derived suppressor cells play crucial roles in the regulation of mouse collagen-induced arthritis[J]. J Immunol, 2013, 191(3): 1073-1081. DOI: 10.4049/jimmunol.1203535.
|
[5] |
AARTS CEM, KUIJPERS TW. Neutrophils as myeloid-derived suppressor cells[J]. Eur J Clin Invest, 2018, 48 (Suppl 2): e12989. DOI: 10.1111/eci.12989.
|
[6] |
HAILE LA, GAMREKELASHVILI J, MANNS MP, et al. CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice[J]. J Immunol, 2010, 185(1): 203-210. DOI: 10.4049/jimmunol.0903573.
|
[7] |
JITSCHIN R, BRAUN M, BÜTTNER M, et al. CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote Tregs[J]. Blood, 2014, 124(5): 750-760. DOI: 10.1182/blood-2013-12-546416.
|
[8] |
VASQUEZ-DUNDDEL D, PAN F, ZENG Q, et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients[J]. J Clin Invest, 2013, 123(4): 1580-1589. doi: 10.1172/JCI60083
|
[9] |
GABRILOVICH DI, NAGARAJ S. Myeloid-derived suppressor cells as regulators of the immune system[J]. Nat Rev Immunol, 2009, 9(3): 162-174. DOI: 10.1038/nri2506.
|
[10] |
LUAN Y, MOSHEIR E, MENON MC, et al. Monocytic myeloid-derived suppressor cells accumulate in renal transplant patients and mediate CD4(+) Foxp3(+) Treg expansion[J]. Am J Transplant, 2013, 13(12): 3123-3131. DOI: 10.1111/ajt.12461.
|
[11] |
BRONTE V, BRANDAU S, CHEN SH, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards[J]. Nat Commun, 2016, 7: 12150. DOI: 10.1038/ncomms12150.
|
[12] |
CONDAMINE T, MASTIO J, GABRILOVICH DI. Transcriptional regulation of myeloid-derived suppressor cells[J]. J Leukoc Biol, 2015, 98(6): 913-922. DOI: 10.1189/jlb.4RI0515-204R.
|
[13] |
MARIGO I, BOSIO E, SOLITO S, et al. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor[J]. Immunity, 2010, 32(6): 790-802. DOI: 10.1016/j.immuni.2010.05.010.
|
[14] |
HIGHFILL SL, RODRIGUEZ PC, ZHOU Q, et al. Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13[J]. Blood, 2010, 116(25): 5738-5747. DOI: 10.1182/blood-2010-06-287839.
|
[15] |
LECHNER MG, LIEBERTZ DJ, EPSTEIN AL. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells[J]. J Immunol, 2010, 185(4): 2273-2284. DOI: 10.4049/jimmunol.1000901.
|
[16] |
OBERMAJER N, KALINSKI P. Generation of myeloid-derived suppressor cells using prostaglandin E2[J]. Transplant Res, 2012, 1(1): 15. DOI: 10.1186/2047-1440-1-15.
|
[17] |
DUGAST AS, HAUDEBOURG T, COULON F, et al. Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion[J]. J Immunol, 2008, 180(12): 7898-7906. doi: 10.4049/jimmunol.180.12.7898
|
[18] |
ZHANG W, LIANG S, WU J, et al. Human inhibitory receptor immunoglobulin-like transcript 2 amplifies CD11b+Gr1+ myeloid-derived suppressor cells that promote long-term survival of allografts[J]. Transplantation, 2008, 86(8): 1125-1134. DOI: 10.1097/TP.0b013e318186fccd.
|
[19] |
GARCIA MR, LEDGERWOOD L, YANG Y, et al. Monocytic suppressive cells mediate cardiovascular transplantation tolerance in mice[J]. J Clin Invest, 2010, 120(7): 2486-2496. DOI: 10.1172/JCI41628.
|
[20] |
TURNQUIST HR, ZHAO Z, ROSBOROUGH BR, et al. IL-33 expands suppressive CD11b+ Gr-1int and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival[J]. J Immunol, 2011, 187(9): 4598-4610. DOI: 10.4049/jimmunol.1100519.
|
[21] |
ADEEGBE D, SERAFINI P, BRONTE V, et al. In vivo induction of myeloid suppressor cells and CD4+Foxp3+ T regulatory cells prolongs skin allograft survival in mice[J]. Cell Transplant, 2011, 20(6): 941-954. DOI: 10.3727/096368910X540621.
|
[22] |
CHEN G, KHERADMAND T, BRYANT J, et al. Intragraft CD11b+ IDO+ cells mediate cardiac allograft tolerance by ECDI-fixed donor splenocyte infusions[J]. Am J Transplant, 2012, 12(11): 2920-2929. DOI: 10.1111/j.1600-6143.2012.04203.x.
|
[23] |
ARAKAWA Y, QIN J, CHOU HS, et al. Cotransplantation with myeloid-derived suppressor cells protects cell transplants: a crucial role of inducible nitric oxide synthase[J]. Transplantation, 2014, 97(7): 740-747. DOI: 10.1097/01.TP.0000442504.23885.f7.
|
[24] |
LIAO J, WANG X, BI Y, et al. Dexamethasone potentiates myeloid-derived suppressor cell function in prolonging allograft survival through nitric oxide[J]. J Leukoc Biol, 2014, 96(5): 675-684. DOI: 10.1189/jlb.2HI1113-611RR.
|
[25] |
NAKAMURA T, NAKAO T, YOSHIMURA N, et al. Rapamycin prolongs cardiac allograft survival in a mouse model by inducing myeloid-derived suppressor cells[J]. Am J Transplant, 2015, 15(9): 2364-2377. DOI: 10.1111/ajt.13276.
|
[26] |
GAJARDO T, MORALES RA, CAMPOS-MORA M, et al. Exogenous interleukin-33 targets myeloid-derived suppressor cells and generates periphery-induced Foxp3+ regulatory T cells in skin-transplanted mice[J]. Immunology, 2015, 146(1): 81-88. DOI: 10.1111/imm.12483.
|
[27] |
NAKAMURA T, NAKAO T, ASHIHARA E, et al. Myeloid-derived suppressor cells recruit CD4+/Foxp3+ regulatory T cells in a murine cardiac allograft[J]. Transplant Proc, 2016, 48(4): 1275-1278. DOI: 10.1016/j.transproceed.2015.10.060.
|
[28] |
ZHAO Y, SHEN XF, CAO K, et al. Dexamethasone-induced myeloid-derived suppressor cells prolong allo cardiac graft survival through iNOS- and glucocorticoid receptor-dependent mechanism[J]. Front Immunol, 2018, 9: 282. DOI: 10.3389/fimmu.2018.00282.
|
[29] |
NAKAO T, NAKAMURA T, MASUDA K, et al. Dexamethasone prolongs cardiac allograft survival in a murine model through myeloid-derived suppressor cells[J]. Transplant Proc, 2018, 50(1): 299-304. DOI: 10.1016/j.transproceed.2017.11.014.
|
[30] |
SAVAGE TM, SHONTS BA, OBRADOVIC A, et al. Early expansion of donor-specific Tregs in tolerant kidney transplant recipients[J]. JCI Insight, 2018, 3(22):124086. DOI: 10.1172/jci.insight.124086.
|
[31] |
HUANG B, PAN PY, LI Q, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host[J]. Cancer Res, 2006, 66(2): 1123-1131. doi: 10.1158-0008-5472.CAN-05-1299/
|
[32] |
KANG X, ZHANG X, LIU Z, et al. Granulocytic myeloid-derived suppressor cells maintain feto-maternal tolerance by inducing Foxp3 expression in CD4+CD25-T cells by activation of the TGF-β/β-catenin pathway[J]. Mol Hum Reprod, 2016, 22(7): 499-511. DOI: 10.1093/molehr/gaw026.
|
[33] |
PARK MJ, LEE SH, KIM EK, et al. Interleukin-10 produced by myeloid-derived suppressor cells is critical for the induction of Tregs and attenuation of rheumatoid inflammation in mice[J]. Sci Rep, 2018, 8(1): 3753. DOI: 10.1038/s41598-018-21856-2.
|
[34] |
LEE CR, KWAK Y, YANG T, et al. Myeloid-derived suppressor cells are controlled by regulatory T cells via TGF-beta during murine colitis[J]. Cell Rep, 2016, 17(12): 3219-3232. DOI: 10.1016/j.celrep.2016.11.062.
|
[35] |
OKANO S, ABU-ELMAGD K, KISH DD, et al. Myeloid-derived suppressor cells increase and inhibit donor-reactive T cell responses to graft intestinal epithelium in intestinal transplant patients[J]. Am J Transplant, 2018, 18(10): 2544-2558. DOI: 10.1111/ajt.14718.
|
[36] |
KIM JI, LEE MK 4TH, MOORE DJ, et al. Regulatory T-cell counter-regulation by innate immunity is a barrier to transplantation tolerance[J]. Am J Transplant, 2009, 9(12): 2736-2744. DOI: 10.1111/j.1600-6143.2009.02847.x.
|
[37] |
QIAN C, CAO X. Dendritic cells in the regulation of immunity and inflammation[J]. Semin Immunol, 2018, 35: 3-11. DOI: 10.1016/j.smim.2017.12.002.
|
[38] |
MANNON RB. Macrophages: contributors to allograft dysfunction, repair, or innocent bystanders?[J]. Curr Opin Organ Transplant, 2012, 17(1): 20-25. DOI: 10.1097/MOT.0b013e32834ee5b6.
|
[39] |
PANG XL, WANG ZG, LIU L, et al. Immature dendritic cells derived exosomes promotes immune tolerance by regulating T cell differentiation in renal transplantation[J]. Aging (Albany NY), 2019, 11(20): 8911-8924. DOI: 10.18632/aging.102346.
|
[40] |
TSE GH, HUGHES J. Macrophages and transplant rejection: a novel future target?[J]. Transplantation, 2013, 96(11): 946-948. DOI: 10.1097/TP.0b013e3182a4bf20.
|
[41] |
ZAHORCHAK AF, MACEDO C, HAMM DE, et al. High PD-L1/CD86 MFI ratio and IL-10 secretion characterize human regulatory dendritic cells generated for clinical testing in organ transplantation[J]. Cell Immunol, 2018, 323: 9-18. DOI: 10.1016/j.cellimm.2017.08.008.
|
[42] |
RIQUELME P, HAARER J, KAMMLER A, et al. TIGIT+ iTregs elicited by human regulatory macrophages control T cell immunity[J]. Nat Commun, 2018, 9(1): 2858. DOI: 10.1038/s41467-018-05167-8.
|
[43] |
EVERLY MJ, EVERLY JJ, AREND LJ, et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss[J]. Am J Transplant, 2009, 9(5): 1063-1071. DOI: 10.1111/j.1600-6143.2009.02577.x.
|
[44] |
GOODE I, XU H, ILDSTAD ST. Regulatory B cells: the new "it" cell[J]. Transplant Proc, 2014, 46(1): 3-8. DOI: 10.1016/j.transproceed.2013.08.075.
|
[45] |
ÖZKAN B, LIM H, PARK SG. Immunomodulatory function of myeloid-derived suppressor cells during B cell-mediated immune responses[J]. Int J Mol Sci, 2018, 19(5):E1468. DOI: 10.3390/ijms19051468.
|
[46] |
PARK MJ, LEE SH, KIM EK, et al. Myeloid-derived suppressor cells induce the expansion of regulatory B cells and ameliorate autoimmunity in the sanroque mouse model of systemic lupus erythematosus[J]. Arthritis Rheumatol, 2016, 68(11): 2717-2727. DOI: 10.1002/art.39767.
|
[47] |
SHEN M, WANG J, YU W, et al. A novel MDSC-induced PD-1-PD-L1+ B-cell subset in breast tumor microenvironment possesses immuno-suppressive properties[J]. Oncoimmunology, 2018, 7(4):e1413520. DOI: 10.1080/2162402X.2017.1413520.
|
[48] |
GAZDIC M, SIMOVIC MARKOVIC B, VUCICEVIC L, et al. Mesenchymal stem cells protect from acute liver injury by attenuating hepatotoxicity of liver natural killer T cells in an inducible nitric oxide synthase- and indoleamine 2, 3-dioxygenase-dependent manner[J]. J Tissue Eng Regen Med, 2018, 12(2): e1173-e1185. DOI: 10.1002/term.2452.
|
[49] |
XUE Q, YAN Y, ZHANG R, et al. Regulation of iNOS on immune cells and its role in diseases[J]. Int J Mol Sci, 2018, 19(12):E3805. DOI: 10.3390/ijms19123805.
|
[50] |
CZYSTOWSKA-KUZMICZ M, SOSNOWSKA A, NOWIS D, et al. Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma[J]. Nat Commun, 2019, 10(1): 3000. DOI: 10.1038/s41467-019-10979-3.
|
[51] |
NELP MT, KATES PA, HUNT JT, et al. Immune-modulating enzyme indoleamine 2, 3-dioxygenase is effectively inhibited by targeting its apo-form[J]. Proc Natl Acad Sci U S A, 2018, 115(13): 3249-3254. DOI: 10.1073/pnas.1719190115.
|
[52] |
MOUGIAKAKOS D, JITSCHIN R, VON BAHR L, et al. Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation[J]. Leukemia, 2013, 27(2): 377-388. DOI: 10.1038/leu.2012.215.
|
[53] |
MAEDA A, EGUCHI H, NAKAHATA K, et al. Monocytic MDSCs regulate macrophage-mediated xenogenic cytotoxicity[J]. Transpl Immunol, 2015, 33(2): 140-145. DOI: 10.1016/j.trim.2015.07.002.
|
[54] |
WANG X, BI Y, XUE L, et al. The calcineurin-NFAT axis controls allograft immunity in myeloid-derived suppressor cells through reprogramming T cell differentiation[J]. Mol Cell Biol, 2015, 35(3): 598-609. DOI: 10.1128/MCB.01251-14.z
|
[55] |
HOLMGAARD RB, ZAMARIN D, LI Y, et al. Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner[J]. Cell Rep, 2015, 13(2): 412-424. DOI: 10.1016/j.celrep.2015.08.077.
|
[56] |
SUN C, MEZZADRA R, SCHUMACHER TN. Regulation and function of the PD-L1 checkpoint[J]. Immunity, 2018, 48(3): 434-452. DOI: 10.1016/j.immuni.2018.03.014.
|
[57] |
DENG L, LIANG H, BURNETTE B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice[J]. J Clin Invest, 2014, 124(2): 687-695. DOI: 10.1172/JCI67313.
|
[58] |
GAO W, DEMIRCI G, STROM TB, et al. Stimulating PD-1-negative signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival[J]. Transplantation, 2003, 76(6): 994-999. doi: 10.1097/01.TP.0000085010.39567.FB
|
[59] |
LIGOCKI AJ, NIEDERKORN JY. Advances on non-CD4+ Foxp3+ T regulatory cells: CD8+, type 1, and double negative T regulatory cells in organ transplantation[J]. Transplantation, 2015, 99(8): 1553-1559.DOI: 10.1097/TP.0000000000000813.
|